Answers are grounded in this paper and cite their sources.
Despite considerable progress elucidating the cellular and molecular events associated with chronic inflammatory bowel diseases (IBD), the etiology of Crohn's disease (CD) and ulcerative colitis (UC), are still largely unknown. However, studies in animal models of IBD have provided a better understanding of the role played by immune and nonimmune cells, as well as their inflammatory mediators, in the development of chronic intestinal inflammation (1). From these studies, it appears that the unregulated production of proinflammatory molecules, perhaps due to the lack of effective immunosuppressive mechanisms in a genetically susceptible individual, leads to the development of disease (2). Signal transduction events associated with the production of inflammatory mediators by various immunoregulatory and effector cells has been the focus of intense research. This review will discuss recent findings regarding the signaling events leading to activation of the IκB/NF (nuclear factor)-κB transcriptional system and the therapeutic relevance of this pathway for IBD. The ubiquitous inducible transcription factor NF-κB is a member of the Rel protein family (3,4) which share a conserved Rel-homology domain (RHD) responsible for DNA binding activity, dimerization and nuclear translocation. NF-κB family members include cRel, RelA (p65), RelB, p50 (precursor NF-κB1), and p52 (precursor NF-κB2) (3,4), which bind the consensus decameric sequence 5′-GGGRNYYYCC-3′ as homo- or heterodimers (5). The most common form of NF-κB is the p50/p65 heterodimer. NF-κB activity is triggered by numerous agents, including interleukin (IL)-1, tumor necrosis factor (TNF)α, lipopolysaccharides (LPS), bacteria, viruses, and viral transactivators (6,7). Activated NF-κB transcriptionally up-regulates many genes involved in practically every phase of the immune response, including IL-1β, TNFα, IL-2, IL-6, IL-8, IL-12, iNOS, COX-2, ICAM-1, VCAM-1, TCR-α (T-cell receptor-α), and major histocompatibility complex (MHC) class II molecules (Table 1) (6,7). Because NF-κB regulates many of the genes associated with the pathogenesis of IBD (8), and is activated by most of the cytokines and bacterial products relevant to these disorders, this molecule provides an attractive target for central blockade of the inflammatory response. Genes regulated by NF-κB Genes regulated by NF-κB NF-κB-dependent gene expression is predominantly regulated by a shuttling system that controls the cytoplasmic versus nuclear localization of this transcription factor. Thus, NF-κB sequestered in the cytoplasm is an inactive state whereas in the nucleus, it binds to specific promoter elements to induce transcription of κB-dependent genes. NF-κB nuclear translocation and DNA binding activity require the proteolytic degradation of the endogenous cytoplasmic inhibitors IκBs (6). These cytoplasmic proteins associate with NF-κB and prevent its nuclear migration by masking the nuclear localization signal (5). IκB molecules belong to a family of proteins that include IκBα, IκBβ, IκBε, IκBγ, Bc13, p105, and p100 (9,10). IκBα is the best characterized and studied NF-κB inhibitor, therefore this protein will be the focus of this review. Degradation of IκBα is initiated by phosphorylation of serine residues 32 and 36, located at the N-terminus of the protein, by the IκB kinase complex (IKK) (Fig. 1) (11,–13). Phosphorylated IκBα undergoes multiple ubiquination steps and is then rapidly degraded (<10min) through a nonlysosomal, adenosine triphosphate (ATP)-dependent 26S proteolytic complex composed of a 700 κD proteasome (14,–16). NF-κB is then freed from the inhibitory effect of complexing with IκB and migrates to the nucleus where it induces κB-dependent gene expression. Tumor necrosis factor (TNF), Fas, interleukin (IL)-1 and lipopolysaccharides (LPS) binding to their respective receptors elicit a cascade of transductional signals that converge on the IκB kinase (IKK) complex. Activated IKK phosphorylates IκBα and triggers the ubiquitination/degradation cascade that releases NF-κB, which then translocates to the nucleus. Nuclear NF-κB binds to κB-promoter elements and transcriptionally activates numerous proinflammatory genes. Because of it central role in regulating expression of many genes implicated in various inflammatory disorders, NF-κB represents a potential target for therapeutic intervention. Because the multicomponent cascade leading to IκB phosphorylation/degradation and NF-κB activation offers multiple potential targets, this review will discuss which components of this complex signaling pathway provides the best therapeutic point for intervention in inflammatory disorders such as IBD. There is limited data available on NF-κB signal transduction in IBD (7). Our current knowledge of the NF-κB signaling pathway comes from investigations of cytokine signal transduction in transformed lymphocytes and epithelial cells. From these studies, it appears that cytokine receptors utilize a bridging system linking their cytoplasmic tails to the IKK complex. This bridging system is composed of various scaffolding and adaptor proteins that activate a cascade of kinases that transmit the signal to the target IκB/NF-κB system (Fig. 1). Due to the complexity of NF-κB signal transduction, this review will be restricted to IL-1β, TNFα, and LPS signaling to the NF-κB system, although other physiological activators such as Fas ligation can also activate this pathway (17). TNFα ligation to the TNF receptor-1 (TNFR1) causes the receptor to trimerize and initiates the recruitment of TNFR1-associated death domain (TRADD) to the cytoplasmic portion of the TNFR1 (Fig. 1) (18,19). TRADD in turn associates with the TNF receptor-associated factor (TRAF)-2 and the receptor-interacting protein (RIP). IL-1β initiates its signaling cascade by dimerizing with the IL-1 receptor accessory protein (IL-1RAcp). This triggers the recruitment of the myeloid differentiation protein 88 (MyD88) and the IL-1 receptor-associated kinase (IRAK), which relay the signal to TRAF-6 and then to the transforming growth factor-β-activated kinase 1 (TAK1) (20,–24). Another signaling pathway relevant to intestinal inflammation is initiated by bacterial products such as LPS. Interestingly, LPS signaling seems to involved the participation of the Toll-like receptors (TLR) (25,–27), which then use components of the IL-1 pathway such as MyD88, IRAK, and TRAF-6 to activate NF-κB (28). Of interest for therapeutic intervention, the TNFα, IL-1β, and LPS signals appear to converge on the NF-κB-inducing kinase (NIK) and the MEK kinase 1 (MEKK1), which associate/activate the IKK complex (29,–31). The IKK complex is composed of the catalytic subunits IKK-α and IKK-β and the scaffolding proteins IKK-γ/Nemo and IKK-complex-associated protein (IKAP) (32). The activated IKK complex selectively phosphorylates IκBα at the specific serine residues, which signal for its ubiquitination and degradation. Of note, IKK activation appears to be the limiting event in IκBα phosphorylation/degradation and NF-κB activation (32). The MAP3K-related kinase NIK and the MEK kinase 1 (MEKK1) are thought to be proximal inducers of the IKK catalytic subunit (33,34). When transiently overexpressed, both proteins induce IKK kinase activity, IκBα serine phosphorylation and NF-κB-dependent gene transcription (31,35,–42). Interestingly, these two MAP3K kinases are likely to differentially induce IKK complex since MEKK1 is a strong inducer of IKKβ kinase activity, whereas NIK preferentially induces IKKα kinase activity (39,40). The exact position and physiological function of these two kinases in NF-κB signaling pathway have yet to be elucidated. The complex cascade of adapter and scaffolding proteins involved in NF-κB activation may represent valuable therapeutic targets, and their importance and potential roles will be discussed. Cellular responses to proinflammatory molecules can be modulated by several means including blockade of synthesis by pharmacologic inhibitors, antisense oligonucleotides or immunosuppressive substances, by inhibition of activity by antibody neutralization, or by receptor blockade or signaling interruption. The redundancy of the cytokine network, in conjunction with the limited knowledge of which key molecules (or combination of molecules) mediate IBD, render selective targeting a difficult challenge. Due to its central role in gene expression, blocking NF-κB activity would potentially inhibit a number of proinflammatory molecules. This approach is conceptually superior to independently blocking each different mediator and could have a strong impact on the course of multiplex inflammatory disorders such as IBD. NF-κB activity has been modulated downstream of IκBα phosphorylation by a number of inhibitory agents (7,43), including proteasome inhibitors and antisense p65 oligonucleotides, which are efficient in inhibiting experimental colitis (44,45). However, the role and importance of signaling molecules upstream of IκBα has not yet been fully investigated, despite the potential advantages of blocking more proximal components of this pathway. The creation of mice homozygous for null mutation of various signaling molecules has greatly improved our knowledge of the mechanisms of NF-κB activation. In the TNFα signaling cascade, embryonic fibroblasts (EF) isolated from TRAF-2-/- mice display a lack of TNFα-mediated c-jun N-terminal kinase (JNK) activity, but not for NF-κB activation (46). This is in agreement with a report showing that TRAF-2 is not the sole protein responsible for TNFα-induced NF-κB activation and IL-8 gene expression in intestinal epithelial cells (47). In contrast, EF isolated from RIP-/- mice display impaired TNFα-mediated NF-κB activation, but not JNK activity (48). This suggests that TNFα signaling is uncoupled at the RIP/TRAF-2 levels, allowing the signal to branch to the NF-κB and JNK pathway, respectively. IL-1β signaling has also been clarified by gene deletion studies. In lymphocytes isolated from MyD88-/- mice, IL-1β failed to induce NF-κB activity, which is accompanied by inhibition of TNFα and IL-6 gene expression (49). Interestingly, LPS-induced NF-κB activation is only delayed in macrophages and lymphocytes isolated from MyD88-/- mice compared with cells isolated from wild-type animals, but induction of TNFα and IL-6 gene expression is inhibited (50). This suggests that LPS utilizes an additional mechanism to mediate TNFα and IL-6 gene expression. One potential mechanism may be induction of phosphorylation of NF-κB bound to DNA through the action of an unknown kinase (51). The next kinase after MyD88 in the IL-1β signaling cascade is IRAK. Fibroblasts isolated from IRAK-/- mice reveal functional IL-1β-mediated NF-κB activity, slightly impaired JNK activity but inhibition of IL-6 gene expression (52). It has been shown that IRAK-2 transmits IL-1β signals to NF-κB, and this may explain the observed NF-κB activity in the absence of IRAK (53). TRAF-6 is the adapter protein that interacts with IRAK. Interestingly, fibroblasts isolated from TRAF-6-/- mice are totally impaired in both IL-1β-mediated NF-κB and JNK activity (54). From these studies, it appears that RIP, MyD88, and TRAF-6, but not TRAF-2 and IRAK, represent effective targets for selective inhibition of the TNF and IL-1β signaling to NF-κB. However, selective blockade of these adapter protein and kinases will inhibit either IL-1β (MyD88 and TRAF-6) or TNFα (RIP) signal transduction, but not both molecules. This represent a therapeutic limitation, since both IL-1β and TNFα expression is increased in chronic intestinal inflammation (1,2,8). A theoretically more powerful means to manipulate the NF-κB pathway is to target a molecule promiscuously utilized during activation of multiple cell membrane receptors. Of interest, NF-κB inducing agents such as IL-1β, TNFα, LPS, and Fas all use NIK to activate NF-κB (Fig. 1), therefore this protein may represent a valuable global target for therapeutic manipulation. There is currently no null mutation for NIK available to study the physiologic role of this protein in cytokine signaling to NF-κB. However, EF isolated from the alymphoplasia (aly) mouse, which is caused by a point mutation in the NIK gene, reveal that lymphotoxin β, but not TNFα-mediated NF-κB activation, is impaired (55,56). Interestingly, using adenoviral gene transfer of a dominant negative NIK, we found that NIK is dispensable for IL-1β and TNFα-induced NF-κB activity and IL-8 gene expression in intestinal epithelial cells (IECs) (57). In addition, simultaneous blockade of MEKK1 and NIK signaling is not sufficient to prevent cytokineinduced IKK and NF-κB activity in IECs (57). Analysis of cells isolated from MEKK1-/- mice should help clarify the role of this kinase in cytokine-induced NF-κB activation. Together, these data indicate that NIK is not an optimal candidate for manipulation of cytokineinduced NF-κB signaling. An important contribution to the field of NF-κB signaling was the cloning and characterization of the inducible kinase complex responsible for IκBα phosphorylation (36,58,59). Numerous studies have identified IKK-α and IKK-β as the two kinase subunits responsible for cytokine-induced IκBα phosphorylation and NF-κB activation (35,58,60,–62). Interestingly, EF isolated from IKK-β-/- mice are unresponsive to IL-1β or TNFα with respect to NF-κB activation (63). This is in sharp contrast to IKK-α-/- mice, which display functional cytokine-mediated NF-κB activation (64,65). In addition, using adenoviral gene transfer of a catalytically inactive IKK-α, we found that cytokine-induced NF-κB activity and IL-8 gene expression required the participation of IKK-β but not IKK-α in IECs (57). However, in vitro analysis reveals that IKK-α modulates IKK-β activity within the IKK-α/IKK-β heterodimer complex, which is the major IKK complex (61,66). The physiological roles of IKAP and IKK-γ in regulating IKK complex activity are still unclear. Therefore, more data are needed to understand the role and function of each IKK subunit in the activation of the IKK complex. Nevertheless, IKK-β seems to be a critical subunit in cytokine-induced IKK activity and subsequent NF-κB activation. Most of the data on cytokine signaling to NF-κB in null mice were obtained using isolated lymphocytes and cultured fibroblast cells. Therefore, it is still unknown whether mucosal cells (monocytes and macrophages, epithelial, and mesenchymal cells) isolated from the intestine of these mice have a similar signaling pathway as their peripheral lymphocyte and fibroblast counterparts. Of interest, we found that intestinal epithelial cells have a unique NF-κB signaling pathway compared with cells derived from hematopoietic lineage cells in respect to 1) delayed, incomplete IRAK and IκBα degradation; 2) TRAF-2 involvement in IL-1β signaling; and 3) limited IKK-β activity (47,67,–69). In addition, NIK is important for CD-40 signaling in primary B cells, but is not required for TNFα-induced NF-κB activation in dendritic cells, suggesting cell specificity in respect to NIK signaling (55). It is evident that more data are needed to fully understand the role of signaling molecules involved in NF-κB activation in mucosal cells. Nevertheless, it appears from the above studies that several signaling molecules are potential targets for NF-κB inhibition, with IKK-β being a prime target (Fig. 2). This kinase is used by multiple upstream activators, and is a prerequisite to NF-κB activation. Blocking its activity should prevent cellular activation and gene expression by a number of stimuli, and have a profound impact on inflammation by simultaneously blocking transcription of multiple proinflammatory cytokines, adhesion molecules, and accessory proteins known to be involve in the inflammatory response. Cytokine-induced NF-κB activation could be blocked at various levels using either pharmacologic inhibitors, antisense oligonucleotides, or viral delivery (gene Rx) of dominant negative molecules. IBD appears to be the consequences of dysregulated production of multiple inflammatory mediators from various effector cells that amplify the immune response, mediate tissue damage, and participate in the development of clinical symptoms such as diarrhea and pain. Many drugs used to manage IBD, such as mesalamine, corticosteroids, and sulfasalazine, have been shown to inhibit NF-κB activity (7). Despite their documented efficacy, these drugs lack specificity, and corticosteroids in particular have many deleterious side effects. The development of new improved drugs with less toxicity would necessitate identification of more selective therapeutic targets, which have control regulatory activities. It is our belief that understanding signaling mechanisms in mucosal cells would help design new specific inhibitors of the NF-κB pathway. Several strategies could be employed, including pharmacologic inhibitors, antisense oligonucleotides, or delivery of dominant negative molecules by gene therapy (Fig. 2). Gene deletion techniques have narrowed the search for a target, suggesting that IKK-β is a consensus candidate molecule. This kinase has been shown to be critical in IL-1β, TNFα, and Fas-mediated NF-κB activity and IL-8 gene expression in IEC (57,70). Alternative targets include the proteasome pathway, which degrades IκBα following its phosphorylation, or interfering with NF-κB nuclear translocation or DNA binding (43). It must be noted, however, that NF-κB blockade does not completely block all inflammatory responses, since other signaling pathways such as signal transducers and activators of transcription (STAT), nuclear factor of activated T cells are involved in transcriptional activation of NF-κB-independent molecules such as interferon-γ. One needs to design a selective way to block the kinase activity of IKK-β during inflammation. Modulation of IKK activity may be accomplished by blocking its gene expression, by preventing its enzyme activation, by reducing catalytic enzyme activity, or by inhibiting substrate (IκB) binding activity. Practical implantation of these strategies will require more detailed biochemical and pharmacological studies of the IKK complex. A number of agents are under development. Of interest, aspirin and salicylate have been shown to inhibit IKK-β activity by competing with the ATP binding site (71) and the dietary product curcumin blocks IKK activity by mechanisms yet to be identified (70). An alternative way of selectively blocking IKK-β is to use antisense oligonucleotides. This strategy should provide valuable data regarding the efficacy of this target in animal models of experimental colitis. The antisense oligonucleotide approach has been successfully employed in experimental colitis using the p65 subunit of NF-κB as a target (44). Finally, an innovative delivery mechanism to epithelial cells could use the type III secretion system of Yersinia spp. These microorganisms deliver several modulator proteins named Yersinia outer proteins (Yops) into the cytoplasm of host cells (72). Recently, YopJ has been shown to block NF-κB activity by preventing IκBα phosphorylation (73). This may be related to the ability of YopJ to bind to IKKβ (74), although no direct evidence exist regarding its inhibitory effect on the IKK complex. Since NF-κB is involved in many aspects of cellular function such as cell growth, proliferation, and apoptosis, one must be cautious when inhibiting its activity. Transient inhibition or local administration should minimize the deleterious effects of blocking NF-κB. The NF-κB signaling pathway represents a new and exciting era of research for intestinal inflammatory diseases that will provide new targets for effective therapeutic manipulation.
No takes yet. Share an insight, caveat, or question.
Jobin et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: